Geldanamycin promotes premature mitotic entry and micronucleation in irradiated p53/p21 deficient colon carcinoma cells

Oncogene

Volumn 27, Issue 42, 2008, Pages 5567-5577

  Moran, D M ^a   Gawlak, G ^a   Jayaprakash, M S ^a   Mayar, S ^a   Maki, C G ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

HSP90; Micronuclei; p53; Radiation

Indexed keywords

CHECKPOINT KINASE 1; CYCLIN DEPENDENT KINASE 1; GELDANAMYCIN; HISTONE H2AX; PROTEIN P21; PROTEIN P53; REGULATOR PROTEIN; UNCLASSIFIED DRUG; WEE1 PROTEIN;

ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL MUTANT; CELL SURVIVAL; CLONOGENIC ASSAY; COLON ADENOCARCINOMA; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IONIZING RADIATION; MITOSIS; NULL CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WILD TYPE;

BENZOQUINONES; CELL DIVISION; COLONIC NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; G2 PHASE; HCT116 CELLS; HSP90 HEAT-SHOCK PROTEINS; HT29 CELLS; HUMANS; LACTAMS, MACROCYCLIC; MICRONUCLEI, CHROMOSOME-DEFECTIVE; MITOSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 52149120751     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.172     Document Type: Article

References (42)

1. Arlander SJ, Eapen AK, Vroman BT, McDonald RJ, Toft DO, Karnitz LM. (2003). Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress. J Biol Chem 278: 52572-52577.
2. Banerji U, O'Donnell A, Scurr M, Pacey S, Stapleton S, Asad Y et al. (2005). Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 23: 4152-4161.
3. Bisht KS, Bradbury CM, Mattson D, Kaushal A, Sowers A, Markovina S et al. (2003). Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity. Cancer Res 63: 8984-8995.
4. Bull EE, Dote H, Brady KJ, Burgan WE, Carter DJ, Cerra MA et al. (2004). Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17- demethoxygeldanamycin. Clin Cancer Res 10: 8077-8084.
5. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP et al. (1998). Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282: 1497-1501.
6. Burma S, Chen BP, Murphy M, Kurimasa A, Chen DJ. (2001). ATM phosphorylates histone H2AX in response to DNA double-strand breaks. J Biol Chem 276: 42462-42467.
7. Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, Kroemer G. (2004). Cell death by mitotic catastrophe: a molecular definition. Oncogene 23: 2825-2837.
8. Deng C, Zhang P, Harper JW, Elledge SJ, Leder P. (1995). Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82: 675-684.
9. Dixon H, Norbury CJ. (2002). Therapeutic exploitation of checkpoint defects in cancer cells lacking p53 function. Cell Cycle 1: 362-368.
10. Dote H, Burgan WE, Camphausen K, Tofilon PJ. (2006). Inhibition of hsp90 compromises the DNA damage response to radiation. Cancer Res 66: 9211-9220.
11. Giono LE, Manfredi JJ. (2006). The p53 tumor suppressor participates in multiple cell cycle checkpoints. J Cell Physiol 209: 13-20.
12. Goes FS, Martin J. (2001). Hsp90 chaperone complexes are required for the activity and stability of yeast protein kinases Mik1, Wee1 and Swe1. Eur J Biochem 268: 2281-2289.
13. Grem JL, Morrison G, Guo XD, Agnew E, Takimoto CH, Thomas R et al. (2005). Phase I and pharmacologic study of 17-(allylamino)-17- demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol 23: 1885-1893.
14. Iliakis G, Wang Y, Guan J, Wang H. (2003). DNA damage checkpoint control in cells exposed to ionizing radiation. Oncogene 22: 5834-5847.
15. Inoue T, Geyer RK, Howard D, Yu ZK, Maki CG. (2001). MDM2 can promote the ubiquitination, nuclear export, and degradation of p53 in the absence of direct binding. J Biol Chem 276: 45255-45260.
16. Jackson JR, Gilmartin A, Imburgia C, Winkler JD, Marshall LA, Roshak A. (2000). An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage. Cancer Res 60: 566-572.
17. Jascur T, Brickner H, Salles-Passador I, Barbier V, El Khissiin A, Smith B et al. (2005). Regulation of p21(WAF1/CIP1) stability by WISp39, a Hsp90 binding TPR protein. Mol Cell 17: 237-249.
18. Jonathan EC, Bernhard EJ, McKenna WG. (1999). How does radiation kill cells? Curr Opin Chem Biol 3: 77-83.
19. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC et al. (2003). A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425: 407-410.
20. Kastan MB, Zhan Q, El-Deiry WS, Carrier F, Jacks T, Walsh WV et al. (1992). A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71: 587-597.
21. Kawabe T. (2004). G2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther 3: 513-519.
22. Limoli CL, Kaplan MI, Corcoran J, Meyers M, Boothman DA, Morgan WF. (1997). Chromosomal instability and its relationship to other end points of genomic instability. Cancer Res 57: 5557-5563.
23. Marder BA, Morgan WF. (1993). Delayed chromosomal instability induced by DNA damage. Mol Cell Biol 13: 6667-6677.
24. Morgan WF. (2003a). Non-targeted and delayed effects of exposure to ionizing radiation: I. Radiation-induced genomic instability and bystander effects in vitro. Radiat Res 159: 567-580.
25. Morgan WF. (2003b). Non-targeted and delayed effects of exposure to ionizing radiation: II. Radiation-induced genomic instability and bystander effects in vivo, clastogenic factors and transgenerational effects. Radiat Res 159: 581-596.
26. Noguchi M, Yu D, Hirayama R, Ninomiya Y, Sekine E, Kubota N et al. (2006). Inhibition of homologous recombination repair in irradiated tumor cells pretreated with Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Biochem Biophys Res Commun 351: 658-663.
27. Norbury C, Blow J, Nurse P. (1991). Regulatory phosphorylation of the p34cdc2 protein kinase in vertebrates. EMBO J 10: 3321-3329.
28. Pawlik TM, Keyomarsi K. (2004). Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys 59: 928-942.
29. Rahmani M, Yu C, Dai Y, Reese E, Ahmed W, Dent P et al. (2003). Coadministration of the heat shock protein 90 antagonist 17-allylamino-17- demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells. Cancer Res 63: 8420-8427.
30. Rieder CL, Palazzo RE. (1992). Colcemid and the mitotic cycle. J Cell Sci 102(Part 3): 387-392.
31. Robles AI, Wright MH, Gandhi B, Feis SS, Hanigan CL, Wiestner A et al. (2006). Schedule-dependent synergy between the heat shock protein 90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin and doxorubicin restores apoptosis to p53-mutant lymphoma cell lines. Clin Cancer Res 12: 6547-6556.
32. Roninson IB, Broude EV, Chang BD. (2001). If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist Updat 4: 303-313.
33. Russell KJ, Wiens LW, Demers GW, Galloway DA, Le T, Rice GC et al. (1996). Preferential radiosensitization of G1 checkpoint-deficient cells by methylxanthines. Int J Radiat Oncol Biol Phys 36: 1099-1106.
34. Sarkaria JN, Busby EC, Tibbetts RS, Roos P, Taya Y, Karnitz LM et al. (1999). Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res 59: 4375-4382.
35. Sasaki M, Nie L, Maki CG. (2007). MDM2 binding induces a conformational change in p53 that is opposed by heat-shock protein 90 and precedes p53 proteasomal degradation. J Biol Chem 282: 14626-14634.
36. Sherr CJ. (1994). G1 phase progression: cycling on cue. Cell 79: 551-555.
37. Shintani S, Zhang T, Aslam A, Sebastian K, Yoshimura T, Hamakawa H. (2006). P53-dependent radiosensitizing effects of Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin on human oral squamous cell carcinoma cell lines. Int J Oncol 29: 1111-1117.
38. Sugimoto K, Sasaki M, Isobe Y, Tsutsui M, Suto H, Ando J et al. (2007). Hsp90-inhibitor geldanamycin abrogates G(2) arrest in p53-negative leukemia cell lines through the depletion of Chk1. Oncogene; e-pub ahead of print 10 December 2007.
39. Waldman T, Lengauer C, Kinzler KW, Vogelstein B. (1996). Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 381: 713-716.
40. Wang Y, Decker SJ, Sebolt-Leopold J. (2004). Knockdown of Chk1, Wee1 and Myt1 by RNA interference abrogates G2 checkpoint and induces apoptosis. Cancer Biol Ther 3: 305-313.
41. Wang Y, Li J, Booher RN, Kraker A, Lawrence T, Leopold WR et al. (2001). Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator. Cancer Res 61: 8211-8217.
42. Whitesell L, Lindquist SL. (2005). HSP90 and the chaperoning of cancer. Nature reviews. Cancer 5: 761-772.